Literature DB >> 19525925

Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas.

Timo Gaiser1, Andreas Waha, Franziska Moessler, Thomas Bruckner, Torsten Pietsch, Andreas von Deimling.   

Abstract

The epidermal growth factor receptor (EGFR) is amplified in approximately 40% of glioblastomas making it a compelling molecular target for therapy. Before starting a therapy targeting the EGFR pathway, accurate determining of EGFR status is a prerequisite. We evaluated the reliability of the novel automated silver enhanced in situ hybridization for the detection of EGFR gene amplification in human glioblastomas. EGFR-amplification status was assessed in 93 cases of glioblastoma by silver enhanced in situ hybridization and compared with results of fluorescence in situ hybridization and immunohistochemistry. In a second cohort, silver enhanced in situ hybridization status was correlated with EGFR gene expression data. The EGFR gene was amplified in 25/90 tumours (28%) by silver enhanced in situ hybridization, and in 28/93 tumours (30%) by fluorescence in situ hybridization. The concordance rate for silver enhanced in situ hybridization and fluorescence in situ hybridization was 98%. Two glioblastomas were scored as being amplified by fluorescence in situ hybridization but not by silver enhanced in situ hybridization. Polymerase chain reaction-based EGFR-amplification data were highly correlated with EGFR silver enhanced in situ hybridization. Altogether, 81 of 91 cases (89%) showed positivity for EGFR expression by immunohistochemistry. Although EGFR protein over expression was associated with gene amplification (r=0.40, P<0.001), there were 29 of 91 cases that showed a high EGFR protein level and no EGFR amplification by fluorescence in situ hybridization. The high concordance rate of silver enhanced in situ hybridization and fluorescence in situ hybridization for the detection of EGFR amplification in paraffin-embedded glioblastomas samples demonstrates that silver enhanced in situ hybridization is a valid and attractive alternative to fluorescence in situ hybridization. Silver enhanced in situ hybridization combines the advantages of bright field microscopy with fully automated analysis in a cost-effective way thereby emphasizing its use for routine application in surgical pathology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19525925     DOI: 10.1038/modpathol.2009.86

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  3 in total

Review 1.  [In situ hybridization in clinical pathology. Significance of polysomy 17 for HER2 determination and genetic tumor heterogeneity in breast cancer].

Authors:  T Gaiser; J Rüschoff; R Moll
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

Review 2.  Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.

Authors:  Aaron M Gruver; Ziad Peerwani; Raymond R Tubbs
Journal:  J Clin Pathol       Date:  2010-03       Impact factor: 3.411

3.  Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.

Authors:  Elena García-García; Carlos Gómez-Martín; Bárbara Angulo; Esther Conde; Ana Suárez-Gauthier; Magdalena Adrados; Cristian Perna; José Luis Rodríguez-Peralto; Manuel Hidalgo; Fernando López-Ríos
Journal:  Histopathology       Date:  2011-07       Impact factor: 5.087

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.